Krystexxa (Pegloticase)

Pegloticase is a medicine used to treat severe, long-lasting gout that has not gotten better with other gout medicines. It is given as an infusion into a vein. It works by breaking down uric acid, the substance that builds up and causes gout.

Brand names:Krystexxa
Medication

What people taking Krystexxa (Pegloticase) report

Every report comes from a Lived member, sent anonymously.

Have you tried Krystexxa (Pegloticase) for Gout?

NameHow it went

About Krystexxa (Pegloticase)

What It's For

Pegloticase, sold as Krystexxa, is an intravenous medicine for adults with chronic gout that has not been controlled by the usual uric acid-lowering pills. Gout happens when uric acid builds up in the blood and forms crystals in and around joints, causing painful flares and, over time, lumps of crystals under the skin called tophi. Most people with gout reach their uric acid goal with daily pills such as allopurinol or febuxostat. Pegloticase is meant for the smaller group whose uric acid stays too high despite the highest appropriate dose of those medicines, or who cannot take them, and who still have frequent flares or tophi that are not shrinking. Rheumatology guidelines advise against using it as a first treatment. It is not used for high uric acid in people without gout symptoms, and it is not approved for children.

How It Works

Pegloticase is a manufactured form of uricase, an enzyme that breaks down uric acid. In the blood, it converts uric acid into allantoin, a harmless substance the kidneys clear easily. This lowers uric acid far faster and further than pills usually do. In studies, average levels fell to about 0.7 mg/dL within a day of the first dose, well below the 6 mg/dL target used in gout care. With uric acid that low, existing crystal deposits, including tophi, can gradually dissolve. The enzyme is attached to polyethylene glycol (PEG), which is what the "peg" in its name refers to. Because pegloticase is a foreign protein, the immune system often makes antibodies against it. Those antibodies can clear the drug quickly, so it stops working, and they also raise the chance of an allergic reaction. Much of how the treatment is given and monitored is designed around this problem.

Dosage & Administration

Pegloticase is given as an infusion into a vein every two weeks at an infusion center or clinic, by staff prepared to treat serious allergic reactions. Each infusion takes about two hours, sometimes longer, and people are usually observed for a while afterward. Before every infusion, people receive medicines to lower the risk of a reaction, typically an antihistamine and a corticosteroid. The recommended approach pairs pegloticase with methotrexate, an immune-suppressing medicine taken as a weekly pill along with folic acid or folinic acid (forms of the B vitamin folate). Methotrexate is started at least four weeks before the first infusion and continued throughout. It makes antibody formation less likely, which helps pegloticase keep working and lowers reaction risk. Pegloticase can be given alone when methotrexate is not safe or appropriate for someone. Oral uric acid-lowering medicines are stopped before treatment begins. Medicine to prevent flares, usually colchicine or an NSAID (a nonsteroidal anti-inflammatory pain reliever), is started at least a week before the first infusion.

Side Effects

Gout flares are the most common side effect, especially in the first three months. This happens because rapidly falling uric acid loosens crystals from the joints. Joint pain, nausea, tiredness, bruising, constipation and vomiting are also reported. Infusion reactions can include hives, itching, skin redness, flushing, chest discomfort or shortness of breath, and most occur during the infusion itself. In the main trial, they affected 4% of people taking methotrexate with pegloticase compared with 31% of those receiving pegloticase alone. If symptoms start during an infusion, tell the nurse right away; staff can slow or stop it. The most serious risk is anaphylaxis, a severe allergic reaction that can be life-threatening. It can happen with any infusion, including the first, and usually begins within two hours, though delayed reactions have been reported. After leaving the clinic, call 911 for trouble breathing, wheezing, swelling of the throat or tongue, trouble swallowing, fainting or a fast, weak heartbeat.

Interactions & Warnings

Pegloticase must not be given to people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme shortage in red blood cells. In these people it can cause life-threatening destruction of red blood cells (hemolysis) and methemoglobinemia, a condition in which blood carries oxygen poorly. G6PD deficiency is more common in people of African, Mediterranean, Middle Eastern and South Asian ancestry, and those at risk are tested before starting. It also should not be given to anyone who has had a serious allergic reaction to it. Allopurinol, febuxostat, probenecid and other uric acid-lowering pills should not be taken during treatment. They can mask the rise in uric acid that signals pegloticase has stopped working, and that signal is what keeps treatment safe. Methotrexate, when used, has its own important risks. It can cause serious harm or death to a developing baby and is not used during pregnancy for conditions like gout, so pregnancy plans need discussion before starting. It is taken once a week, not daily; taking it every day by mistake has caused deaths. It also requires its own blood test monitoring. Pegloticase can worsen congestive heart failure, so people with heart failure are watched closely after infusions. Its effects in pregnancy are not well studied, and it is not known whether it passes into breast milk.

What to Expect

Uric acid is checked with a blood test before each infusion. If it rises above 6 mg/dL, especially on two checks in a row, that usually means antibodies have developed. Treatment is then stopped, because the drug is no longer controlling uric acid and the risk of anaphylaxis is higher. In the main trial, about 71% of people taking pegloticase with methotrexate kept uric acid below 6 mg/dL for most of month six, compared with 39% of those taking pegloticase alone. Flares often get more frequent at first, which can be discouraging. Flare-prevention medicine is usually continued for at least six months, and pegloticase does not need to be stopped because of a flare. Flares tend to ease after the first few months as crystal deposits shrink, and tophi can visibly get smaller or disappear over months of treatment. The best length of treatment has not been established. Restarting after a break of more than four weeks may raise the risk of reactions, so gaps in treatment should be discussed with the care team rather than handled informally.

Questions to Ask Your Doctor

  1. 1.Have I tried the oral uric acid-lowering options long enough, and at a high enough dose, for pegloticase to make sense?
  2. 2.Should I take methotrexate with pegloticase, and what monitoring and pregnancy precautions would that involve?
  3. 3.Do I need a G6PD test before starting?
  4. 4.How will we handle gout flares in the first months, and what uric acid result would make us stop?
  5. 5.How long might I need infusions, and what happens with my gout after they end?

Last reviewed • Oct 2026

Educational content, not medical advice.